Vyome Holdings, Inc. develops clinical-stage specialty pharmaceutical therapies for immune-inflammatory and rare conditions. Company news centers on VT-1953, a topical gel program for malodor and other symptoms of malignant fungating wounds in cancer patients, and VT-1908, a repurposed immune modulator being studied for uveitis.
Recurring updates include clinical and preclinical data presentations, regulatory submissions and development planning, capital-structure actions, material agreements, shareholder voting matters, and operating or financial results tied to Vyome’s pharmaceutical and biotechnology activities.
Vyome (NASDAQ: HIND) filed for Orphan Drug Designation for VT-1953, its lead clinical asset for malignant fungating wounds (MFW).
Key points: potential 7 years U.S. market exclusivity, up to 25% R&D tax credits, a PDUFA fee waiver (~$3M), a third-party rNPV valuation of $455M today and ~$1B post-Phase 3, planned FDA Phase 3 interactions in Q2 2026, CROs engaged, and interim Phase 3 results expected in mid-2027.
Vyome Holdings (Nasdaq: HIND) funded the estimated costs to reach initial Phase 3 interim results for VT-1953, aimed at treating symptoms of Malignant Fungating Wounds, using its existing ATM facility. On January 27, 2026, the company sold 1,089,045 shares at an average price of $5.00, generating approximately $5.29 million net proceeds.
As of January 29, 2026, Vyome reported $9.5 million cash on hand and total shares outstanding of 7,008,882. Management says interim Phase 3 findings are anticipated in mid-2027.
Vyome (NASDAQ: HIND) released results of an independent U.S. market and valuation analysis for lead candidate VT-1953 on January 27, 2026. The third‑party study estimates the U.S. total addressable pharmacologic market for malignant fungating wounds at USD 2.2 billion, modeled peak annual net sales for VT-1953 at ~USD 600 million, a current risk‑adjusted asset value of USD 455 million given positive Phase 2 data, and a post‑Phase 3 rNPV approaching USD 1 billion. The analysis used epidemiology modeling, pricing benchmarking, clinician interviews, and rNPV methodology and notes no FDA‑approved drugs currently exist for this indication.
Vyome Holdings (Nasdaq: HIND) subsidiary LiveChain (OTC: LICH) executed a binding letter of intent to acquire a senior secured convertible note in Humanyze from Remus Capital in exchange for LICH common stock valued at ~$325,000. The note is secured by a lien on Humanyze intellectual property and trade secrets, giving LICH senior secured creditor status.
The LOI, dated December 22, 2025, contemplates definitive agreements within 30 days and closing within an additional 45 days, subject to conditions; the company said there is no assurance the transaction will close. Humanyze is an MIT‑originated, AI-enabled HR analytics company with a large employee interaction database.
Vyome (Nasdaq: HIND) reported positive final Phase 2 results for topical VT-1953 in malignant fungating wounds (MFW). The trial met its primary endpoint with investigator-assessed malodor improvement (P=0.002) and showed statistical improvements in patient-reported smell impact on quality of life (P=0.0256) and wound pain (P=0.002). Improvements were observed as early as Day 7 and held at Day 14 versus vehicle (primary comparison P=0.0015; pain vs vehicle P=0.0026). VT-1953 was well tolerated with no new safety concerns. Vyome plans to discuss a pivotal Phase III design with the FDA, target a 2026 pivotal start, and pursue approval to address an estimated $1B addressable market.
Vyome (NASDAQ: HIND) appointed Dr. Aditya Bardia as Senior Medical Advisor to guide clinical development of its lead asset VT-1953 for treatment of symptoms of malignant fungating wounds (MFW).
Vyome said approval for VT-1953 is being targeted in 2026. Dr. Bardia is described as having led clinical development programs that produced approvals for Sacituzumab Govitecan, Trastuzumab Deruxtecan, Datopotamab Deruxtecan and Elacestrant. Vyome called the appointment a milestone as it prepares pivotal studies and aims to design cost-efficient trials for VT-1953.
Vyome Holdings (NASDAQ: HIND) reported its first quarter as a Nasdaq-listed company, highlighting clinical, corporate and financial milestones on November 18, 2025. Interim Phase 2 data for VT-1953 showed a statistically significant reduction in malodor (P<0.001), with reported pain and quality-of-life improvements and an excellent safety profile. The company reported $5.7 million in cash and short-term investments, with an expected runway through the end of 2026. Vyome added a CTO and SVP of Clinical Development, acquired MIT startup Oculo to launch an AI strategy, and plans FDA discussions and orphan-drug activity in H1 2026.
Vyome Holdings (Nasdaq: HIND) held its annual shareholder meeting on October 28, 2025. All three Class I directors — Krishna K. Gupta, Shiladitya Sengupta, and Stash Pomichter — were re-elected to serve until the 2028 annual meeting with 93% of votes cast in favor.
Shareholders ratified Kreit & Chiu CPA LLP as the independent registered public accounting firm for fiscal 2025 and approved the 2025 Equity Incentive Plan and named executive officer compensation. Management emphasized alignment with shareholders, noting independent directors are not taking cash compensation or new equity grants except merger-issuable awards. Vyome said it remains focused on clinical-stage immuno-inflammatory assets across the US–India innovation corridor.
Vyome Holdings (NASDAQ:HIND) has announced the acquisition of Oculo, Inc., an MIT AI spinout, and launched a new business unit focused on using AI to combat inflammation. The company aims to develop an AI psychiatrist trained on US and India data to diagnose and treat systemic inflammation by targeting behavioral drivers and biomarkers.
A newly-formed AI subcommittee of MIT alumni will oversee the initiative, which aims to establish a novel therapeutic category combining mental health, psychoneuroimmunology, and digital health. The company confirms it remains fully funded through 2026 to advance its core biotech assets, with the digital therapeutics market potential estimated at over $100B in the next decade.
Vyome Holdings (NASDAQ: HIND) has strengthened its leadership team with two significant appointments. Dr. Richard Fahrner, with over 25 years of drug development experience and involvement in 17 approved medicines, joins as Chief Technology Officer. Dr. Tamara Agajanov, bringing nearly 30 years of clinical operations expertise, takes the role of Senior Vice President – Clinical Development.
The company is currently conducting a Phase 2 study in malignant fungating wounds (MFW), representing a potential multi-billion dollar market opportunity. Topline results are expected by October 2025. The appointments come at a crucial time as Vyome prepares for pivotal trial studies, with interim Phase 2 results in MFW described as "very encouraging."